Validation of PAG1 as a new risk gene with therapeutic potential for asthma

在澳大利亚，大约10%的成人和儿童患有哮喘。其中60%的人的哮喘症状在现有的治疗方法下没有得到很好的控制，因此需要新的治疗方法。我们最近发现PAG1是一种新的哮喘风险基因。在这项研究中，我们将进行小鼠和人体研究，以调查抑制PAG1可能有助于预防或治疗哮喘急性发作的可能性。

About 10% of adults and children suffer from asthma in Australia. For >60% of these their asthma symptoms are not well controlled with existing treatments and so novel therapies are needed. We have recently identified PAG1 as a novel risk gene for asthma. In this study, we will conduct mouse and human studies to investigate the possibility inhibition of PAG1 might help prevent or treat asthma exacerbations.